Alkermes (ALKS) Cash from Investing Activities (2010 - 2026)
Alkermes (ALKS) posted quarterly Cash from Investing Activities of -$2.4 million for Q2 2026, up 91.75% year-over-year from -$1.3 million in Q2 2025, and up 99.88% quarter-over-quarter from -$2.1 billion in Q1 2026.
Alkermes (ALKS) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Cash from Investing Activities for 17 consecutive years, with -$2.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Investing Activities rose 91.75% year-over-year to -$2.4 million; the TTM figure through Jun 2026 stood at -$1.8 billion (down 1130.68% YoY), while the FY2025 annual figure was $295.5 million, up 365.48% from the prior year.
- Cash from Investing Activities advanced to -$2.4 million in Q2 2026 per ALKS's latest filing, from -$2.1 billion in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $322.3 million in Q4 2025 and bottomed at -$2.1 billion in Q1 2026.
- Historically, Cash from Investing Activities has averaged -$105.9 million across 5 years, with a median of -$10.3 million in 2024.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities soared 3838.54% — and 2026, when it tumbled 22919.16%.
- Alkermes' Cash from Investing Activities stood at $27.7 million in 2022, then slumped by 175.64% to -$21.0 million in 2023, then soared by 33.87% to -$13.9 million in 2024, then soared by 2423.21% to $322.3 million in 2025, then slumped by 100.75% to -$2.4 million in 2026.
- Business Quant data shows ALKS's Cash from Investing Activities at -$2.4 million in Q2 2026, -$2.1 billion in Q1 2026, and $322.3 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.55 Bn | 29.88 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.14 Bn | 19.48 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.75 Bn | 17.87 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.72 Bn | 11.19 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.10 Bn | 7.45 Bn | 397.90 Mn | -2.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.41 Mn |
| Jun 30, 2026 | -2.41 Mn |
| Mar 31, 2026 | -2.08 Bn |
| Mar 31, 2026 | -2.08 Bn |
| Dec 31, 2025 | 322.35 Mn |
| Dec 31, 2025 | 322.35 Mn |
| Sep 30, 2025 | -6.74 Mn |
| Sep 30, 2025 | -6.74 Mn |
| Jun 30, 2025 | -29.21 Mn |
| Jun 30, 2025 | -29.21 Mn |
| Mar 31, 2025 | 9.10 Mn |
| Mar 31, 2025 | 9.10 Mn |
| Dec 31, 2024 | -13.88 Mn |
| Dec 31, 2024 | -13.88 Mn |
| Sep 30, 2024 | -109.33 Mn |
| Sep 30, 2024 | -109.33 Mn |
| Jun 30, 2024 | 51.85 Mn |
| Jun 30, 2024 | 51.85 Mn |
| Mar 31, 2024 | -39.95 Mn |
| Mar 31, 2024 | -39.95 Mn |